Find information on thousands of medical conditions and prescription drugs.

Synthroid

Synthroid is the brand name used by Abbott Laboratories for levothyroxine sodium (T4, a synthetic thyroid hormone) product. Levothyroxine is the basic T4 thyroid hormone responsible for metabolism. Patients who suffer from hypothyroidism, either for endogenous disease or after radioactive iodine ablation or thyroid resection, require exogenous thyroid hormone, and Synthroid is the most prescribed brand of T4. Synthroid was marketed in 1955, but was not FDA approved at that time as it was considered "generally regarded safe". more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
Growth hormone
Salbutamol
Salmeterol
Sandimmune
Sandostatin
Sansert
Saquinavir
Sarafem
Satric
Scopolamine
Seasonale
Secobarbital
Secretin
Selegiline
Semprex-D
Sensipar
Sensorcaine
Serax
Serevent
Serine
Seroquel
Serostim
Serrapeptase
Sertindole
Sertraline
Serzone
Sevelamer
Sevoflurane
Sibutramine
Sildenafil
Silibinin
Simvastatin
Sinemet
Sinequan
Singulair
Sirolimus
Skelaxin
Sodium cyclamate
Solage
Soma
Somatostatin
Sotahexal
Sotalol
Sotret
Spiperone
Spiriva
Spironolactone
Sporahexal
Sporanox
SPS
SSD
Stanozolol
Stavudine
Stelazine
Stilbestrol
Stilbetin
Stimate
Stiripentol
Strattera
Streptokinase
Streptomycin
Suboxone
Subutex
Sucralfate
Sucralfate
Sufentanil
Sulbactam
Sulfamethoxazole
Sulfanilamide
Sulfasalazine
Sulforidazine
Sulla
Sulpiride
Sultamicillin
Sumatriptan
Suprefact
Suramin sodium
Sustaire
Sustiva
Suxamethonium chloride
Symmetrel
Synarel
Synercid
Synthroid
Syntocinon
Zaleplon
T
U
V
W
X
Y
Z

In the 1990s, in response to various complaints, all levothyroxine preparations were required to undergo the formal FDA approval process. Synthroid was approved by the FDA on 2002-07-24.

It should be noted that Synthroid was not the first T4 produced for patients, and there are generic versions approved by the Food and Drug Administration, but Synthroid represented a significant advance on other brands and formulations in terms of uniformity of production and regularity of therapeutic action. Therefore, many endocrinologists and other prescribers specify a specific thyroid hormone brand because thyroid hormone has a narrow therapeutic index. In the United States, Synthroid is the most prescribed drug. Despite its frequent use, however, it is far from being a so-called "blockbuster drug" ($1 billion USD or more in sales annually).

Notes

  • ^  Company Report on Abbott
  • ^  Dr Mercola's site
  • ^  FDA approval

Read more at Wikipedia.org


[List your site here Free!]


Bioequivalence of generic Synthroid questioned
From OB/GYN News, 10/1/04 by Elizabeth Mechcatie

A recently approved generic formulation of levothyroxine "is significantly more potent" than Synthroid, and could lead to serious side effects if a patient were switched from one to the other, two clinical endocrinology organizations have warned.

Bioequivalence data used as the basis of the recent approval of a generic version of levothyroxine indicate that the generic--manufactured by Sandoz and approved in June--"may be as much as one-eighth more potent" than Synthroid, the American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) said in a statement.

This information "confirms our concern that current FDA standards defining the equivalence of levothyroxine products are too lax," and "switching between two products could compromise the effectiveness of treatment," resulting in serious side effects, AACE president Dr. Carlos Hamilton said in the statement.

Levothyroxine has a narrow toxic-to-therapeutic ratio, so "even minor or inadequate dosing" can result in problems for the patient, the statement said. Synthroid, manufactured by Abbott Laboratories, has been the most widely used brand of levothyroxine.

The ATA and AACE recommend that physicians "encourage" their patients on levothyroxine to stay on the same preparation, if possible, although pharmacies may switch products. If the preparation has to be switched, patients will need to have a thyroid-stimulating hormone blood test 4-6 weeks afterward to determine if the dosage needs to be adjusted.

The FDA is evaluating the ATA/AACE statement, and did not have a response at press time.

Michael Roth, who is executive director of communications at Novartis, told this newspaper that the company stands by approval of the Sandoz product, which is "therapeutically bioequivalent to both Synthroid and Levoxyl." (Levoxyl was approved in 2001.) The company has "conducted significant testing of our product to ensure stability and validated that our product does, indeed, match that of the branded counterparts," he said. Sandoz is the generic business unit of Novartis.

BY ELIZABETH MECHCATIE

Senior Writer

COPYRIGHT 2004 International Medical News Group
COPYRIGHT 2004 Gale Group

Return to Synthroid
Home Contact Resources Exchange Links ebay